Thermodynamics, Conformation, and Biocatalytic Performance of Glucose Oxidase Combined with Black Phosphorus Quantum Dots

Glucose oxidase (GOD) has a wide range of applications in biosensing and cancer treatment as a result of its unique biocatalytic properties. More importantly, GOD could synergistically enhance the cancer therapeutic effect when combined with other cancer therapeutic strategies. However, the interaction of GOD with a cancer therapeutic agent has not been well-studied. Herein, the thermodynamic properties of the interaction between black phosphorus quantum dots (BPQDs) and GOD were systematically elucidated, and the dose-dependent conformational and enzymatic activity changes of BPQDs on GOD were quantitatively and qualitatively analyzed. The results indicated that the stoichiometric ratio of BPQDs to GOD was approximately 1:1. In particular, fluorescence spectroscopy, circular dichroism spectra, and Fourier transform infrared spectra have synergistically studied the changes in secondary and tertiary conformations of GOD induced by BPQDs. Higher doses of BPQDs resulted in a loose structure of GOD but still maintained the native conformation and preserved effective enzymatic activity, effectively catalyzing the production of H2O2 from glucose in a cell. The interaction mechanism between BPQDs and GOD provides a theoretical basis for the design of GOD-based multimodal synergistic cancer therapy and its clinical translation analysis

Additional file 1 of Changes in effective connectivity during the visual-motor integration tasks: a preliminary f-NIRS study

Additional file 1. This file shows the details of Methods and significant EC values of different networks (or channels) among the three conditions

Inhibiting immune escape in lung adenocarcinoma: the role of SPARC in suppressing CD276 function

SPARC is an acidic, cysteine-rich, calcium-binding member of the non-collagen glycoproteins originating in bone. Although implicated in the development of several cancers, the functions and mechanisms of SPARC remain unclear. The aim of this study was to investigate whether smooth muscle cell (SMC)-associated SPARC acts an important tumour suppressor in lung adenocarcinoma (LUAD). SPARC inhibits immune evasion in LUAD by suppressing CD276 functionality. We downloaded RNA-sequencing data from patients with LUAD in The Cancer Genome Atlas and identified a set of genes showing SMC-specific expression in these samples. We then screened for differentially expressed genes (DEGs). Enrichment analysis using the Gene Expression Omnibus identified key genes, while immune pathway analysis explored the expression of immune checkpoints involved in LUAD immune regulation. We further validated the differential expression of SPARC and CD276 using immunohistochemistry. Among the upregulated DEGs, SPARC exhibited high enrichment in SMCs, whereas 13 immune checkpoints, such as LAIR1 and CTLA4, were excluded. The infiltration level of the CD276 immune checkpoint was lower in the high-risk group than in the low-risk group. While our results suggest a correlation between SPARC, CD276 and LUAD, additional studies are needed to validate these findings and elucidate the underlying mechanisms before definitive conclusions can be drawn regarding their utility in clinical practice.</p

Multiresponsive Supramolecular Gel Based on Pillararene-Containing Polymers

A multiresponsive supramolecular gel was constructed based on a bis­(pyridinium) dication guest and a copolymer with pillararenes as the pendant groups, which was synthesized by free radical copolymerization of methacrylate-functionalized pillararenes and methyl methacrylate. The mechanism of gel formation was explored by the intensive study. Upon addition of competitive host or guest molecules, pillararene-based gel could be transferred into sol due to the competition of host–guest complexation. Surprisingly, the ordered stacking of pillararenes was indispensable to obtain the supramolecular gel, which endowed the system with response to temperature change

Table_1_The Implicated Roles of Cell Adhesion Molecule 1 (CADM1) Gene and Altered Prefrontal Neuronal Activity in Attention-Deficit/Hyperactivity Disorder: A “Gene–Brain–Behavior Relationship”?.docx

Background: Genes related to cell adhesion pathway have been implicated in the genetic architecture of attention-deficit/hyperactivity disorder (ADHD). Cell adhesion molecule 1, encoded by CADM1 gene, is a protein which facilitates cell adhesion, highly expressed in the human prefrontal lobe. This study aimed to evaluate the association of CADM1 genotype with ADHD, executive function, and regional brain functions.Methods: The genotype data of 10-tag single nucleotide polymorphisms of CADM1 for 1,040 children and adolescents with ADHD and 963 controls were used for case–control association analyses. Stroop color–word interference test, Rey–Osterrieth complex figure test, and trail making test were conducted to assess “inhibition,” “working memory,” and “set-shifting,” respectively. A subsample (35 ADHD versus 56 controls) participated in the nested imaging genetic study. Resting-state functional magnetic resonance images were acquired, and the mean amplitude of low-frequency fluctuations (mALFF) were captured.Results: Nominal significant genotypic effect of rs10891819 in “ADHD-alone” subgroup was detected (P = 0.008) with TT genotype as protective. The results did not survive multiple testing correction. No direct genetic effect was found for performance on executive function tasks. In the imaging genetic study for the “ADHD-whole” sample, rs10891819 genotype was significantly associated with altered mALFF in the right superior frontal gyrus (rSFG, peak t = 3.85, corrected P Conclusions: Our study offered preliminary evidence to implicate the roles of CADM1 in relation to prefrontal brain activities, inhibition function, and ADHD, indicating a potential “gene–brain–behavior” relationship of the CADM1 gene. Future studies with larger samples may specifically test these hypotheses generated by our exploratory findings.</p

Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy

In many types of cancers, pyruvate dehydrogenase kinase (PDK) is abnormally overexpressed and has become a promising target for cancer therapy. However, few highly effective inhibitors of PDK have been reported to date. Herein, we designed and synthesized a series of PDK inhibitors based on dichloroacetate (DCA) and arsenicals. Of the 27 compounds, 1f demonstrated PDK inhibition with high efficiency at a cellular level (IC50 = 2.0 μM) and an enzyme level (EC50 = 68 nM), far more effective than that of DCA. In silico, in vitro, and in vivo studies demonstrated that 1f inhibited PDK, shifted the energy metabolism from aerobic glycolysis to oxidative phosphorylation, and induced cell apoptosis. Moreover, new 1f-loaded nanoparticles were developed, and the administration of high-drug-loading nanoparticles (0.15 mg/kg) caused up to 90% tumor shrinkage without any apparent toxicity. Hence, this study provided a novel metabolic therapy for cancer treatment

Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy

In many types of cancers, pyruvate dehydrogenase kinase (PDK) is abnormally overexpressed and has become a promising target for cancer therapy. However, few highly effective inhibitors of PDK have been reported to date. Herein, we designed and synthesized a series of PDK inhibitors based on dichloroacetate (DCA) and arsenicals. Of the 27 compounds, 1f demonstrated PDK inhibition with high efficiency at a cellular level (IC50 = 2.0 μM) and an enzyme level (EC50 = 68 nM), far more effective than that of DCA. In silico, in vitro, and in vivo studies demonstrated that 1f inhibited PDK, shifted the energy metabolism from aerobic glycolysis to oxidative phosphorylation, and induced cell apoptosis. Moreover, new 1f-loaded nanoparticles were developed, and the administration of high-drug-loading nanoparticles (0.15 mg/kg) caused up to 90% tumor shrinkage without any apparent toxicity. Hence, this study provided a novel metabolic therapy for cancer treatment

Chiral Cu_2–<i>x</i>Se Nanoparticles for Enhanced Synergistic Cancer Chemodynamic/Photothermal Therapy in the Second Near-Infrared Biowindow

Chiral nanomaterials have great potential in improving the clinical therapeutic effect due to the unique chiral selectivity of biosystems. However, such a promising therapeutic strategy has so far received little attention in cancer treatment. Here, we report a first chiral Fenton catalyst, d-/l-penicillamine-modified Cu2–xSe nanoparticles (d-/l-NPs), for enhanced synergistic cancer chemodynamic therapy (CDT) and photothermal therapy (PTT) under the second near-infrared (NIR-II) light irradiation. The chiral effect study of chiral Cu2–xSe NPs on cancer cells shows that d-NPs exhibit stronger CDT-induced cytotoxicity than l -NPs due to the stronger internalization ability. Moreover, the hydroxyl radicals (•OH) produced in d-NP-treated cancer cells via the CDT effect can be further improved by NIR-II light irradiation, thereby increasing the apoptosis of cancer cells. In vivo experiments show that, compared with l-NPs, d-NPs exhibit a stronger photothermal effect on the tumor site under NIR-II light irradiation and could completely eliminate the tumor under the synergistic effect of CDT and PTT. This work shows that the chirality of the surface ligand of the nanomaterials could significantly affect their cancer curative effect, which opens up a new way for the development of anticancer nanomedicine

Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy

In many types of cancers, pyruvate dehydrogenase kinase (PDK) is abnormally overexpressed and has become a promising target for cancer therapy. However, few highly effective inhibitors of PDK have been reported to date. Herein, we designed and synthesized a series of PDK inhibitors based on dichloroacetate (DCA) and arsenicals. Of the 27 compounds, 1f demonstrated PDK inhibition with high efficiency at a cellular level (IC50 = 2.0 μM) and an enzyme level (EC50 = 68 nM), far more effective than that of DCA. In silico, in vitro, and in vivo studies demonstrated that 1f inhibited PDK, shifted the energy metabolism from aerobic glycolysis to oxidative phosphorylation, and induced cell apoptosis. Moreover, new 1f-loaded nanoparticles were developed, and the administration of high-drug-loading nanoparticles (0.15 mg/kg) caused up to 90% tumor shrinkage without any apparent toxicity. Hence, this study provided a novel metabolic therapy for cancer treatment

Quench-Release-Based Fluorescent Immunosensor for the Rapid Detection of Tumor Necrosis Factor α

Tumor necrosis factor α (TNF-α) is used as a biomarker for the diagnosis of various inflammatory and autoimmune diseases. In recent years, numerous approaches have been used for the qualitative and quantitative analyses of TNF-α. However, these methods have several drawbacks, such as a tedious and time-consuming process, high pH and temperature sensitivity, and increased chances of denaturation in vitro. Quenchbody (Q-body) is a fluorescence immunoprobe that functions based on the principle of photoinduced electron transfer and has been successful in detecting various substances. In this study, we constructed two Q-bodies based on a therapeutic antibody, adalimumab, to rapidly detect human TNF-α. Both sensors could detect TNF-α within 5 min. The results showed that the limit of detection (LOD) of TNF-α was as low as 0.123 ng/mL with a half-maximal effective concentration (EC50) of 25.0 ng/mL using the TAMRA-labeled Q-body, whereas the ATTO520-labeled Q-body had a LOD of 0.419 ng/mL with an EC50 of 65.6 ng/mL, suggesting that the Q-bodies could rapidly detect TNF-α with reasonable sensitivity over a wide detection range. These biosensors will be useful tools for the detection and monitoring of inflammatory biomarkers